<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01295034</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 10-0679</org_study_id>
    <secondary_id>R01DA031095</secondary_id>
    <nct_id>NCT01295034</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplements for HIV-positive Patients on cART</brief_title>
  <official_title>Vitamin D Supplements for HIV-positive Patients on cART</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrea Branch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ability of vitamin D to modulate the immune system and strengthen bones may mitigate the
      adverse medication consequences of HIV/AIDS, but little is known about either the health
      benefits of vitamin D supplements, or about the optimal dosing regimen for patients on highly
      active antiretroviral therapy (HAART). This trial is a comparison of two regimens for
      administering vitamin D and calcium to HIV-positive individuals taking antiviral medications.
      This study will help physicians make evidence-based decisions about the most effective way to
      use vitamin D in their patients and enable the design of large multi-center trials in the
      future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the post-HAART era, patients continue to suffer from the adverse medical consequences of
      HIV/AIDS. The adverse effects include incomplete immune reconstitution, chronic inflammation,
      depression, increased risk of cardiovascular and metabolic disease, and low bone density.
      Clinical trials suggest that vitamin D supplements can increase bone density, reduce
      inflammation, alleviate depression, and increase longevity if given in adequate doses. To
      achieve maximum benefits, most vitamin D experts in the HIV field agree that vitamin D
      treatments should raise the concentration of 25-hydroxyvitamin D [25(OH)D] above 30 ng/ml. A
      growing number of HIV care providers desire an evidence-based protocol for achieving these
      25(OH)D target levels. This project addresses the need for a validated protocol for treating
      vitamin D deficiency in HIV-positive individuals on HAART. The goal of Aim I is to conduct a
      12-mo randomized, double-blinded trial comparing two dosing regimens of oral vitamin D plus
      0.5 g/d of calcium in patients on stable HAART who have 25(OH)D levels â‰¤ 25 ng/ml and
      undetectable HIV viral load at baseline (100 per arm). Medication event monitoring system
      (MEMS) caps will be used to record supplement use and to promote adherence. Subjects in
      Protocol A will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin
      D3 for 48 wk. Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on
      the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial
      response. The primary outcome measure is the difference in the percentage of subjects with
      25(OH)D levels in the range of 30-60 ng/ml at 12 mo. The secondary outcome is the slope of
      the 25(OH)D response curve during various time intervals. The goal of Aim II is to compare
      the impact of the two protocols on markers of disease. The primary outcome measure is the
      change in the CD4+T cell count. Secondary outcomes include changes in CD4+ T cell subsets,
      markers of inflammation, markers of bone and calcium metabolism, self-reported psychological
      status, viral load, side effects, safety, and adherence. To our knowledge, this trial is the
      first head-to-head comparison of a regimen that uses a loading dose of vitamin D2 with a
      regimen that uses a tiered starting dose of vitamin D3. The project will yield a validated
      protocol for treating vitamin D deficiency in HIV-infected patients on HAART and will provide
      initial data about the risks and health benefits of vitamin D and calcium supplements. This
      information is essential for designing definitive multicenter trials in the future.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>25(OH)D Levels</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>The difference in the percentage of subjects with 25(OH)D levels in the range of 30-60 ng/ml at 12 mo between the two arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4+T Cell Count</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>The change in the CD4+T cell count between the two arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>HIV-associated Co-morbidities</condition>
  <arm_group>
    <arm_group_label>conventional vitamin D treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiered/titrated vitamin D dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>conventional vitamin D treatment</intervention_name>
    <description>Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.</description>
    <arm_group_label>conventional vitamin D treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiered/titrated vitamin D dosing</intervention_name>
    <description>Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.</description>
    <arm_group_label>tiered/titrated vitamin D dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age, 18-70 yr

          -  HIV-infected

          -  on a stable HAART regimen for at least 12 mo with an undetectable HIV viral load for
             6-mo

          -  willing to participate

          -  not receiving vitamin D supplementation in a form other than vitamin D2 or vitamin D3

          -  not receiving treatment for bone disease

          -  not receiving medications known to alter bone mineralization

          -  not suffering from conditions known to affect vitamin D, calcium, and/or phosphate
             levels (including clinically significant hypocalcemia, primary hyperparathyroidism)

          -  not experiencing kidney disease based on GFR &gt; 60 min/ml/1.73 m2, 10) 25(OH)D level &lt;
             25 ng/ml

          -  not meeting criteria of the National Osteoporosis Foundation for established bone
             disease (osteoporosis, osteomalacia) requiring immediate treatment

          -  not consuming more than 2.0 gm of calcium/day in food and supplements combined outside
             the trial

          -  not consuming more than 800IU/day of vitamin D outside the trial

          -  not suffering from an unstable medical condition likely to preclude participation in a
             12 month trial

          -  able to ingest and absorb food and nutrients

          -  not pregnant or planning to become pregnant.

        Exclusion Criteria:

          -  No history or evidence of HIV infection

          -  HIV viral load positive

          -  outside the age range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea D Branch, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, Aldrovandi GM, Cardoso SW, Santana JL, Brown TT. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010 Oct 15;51(8):937-46. doi: 10.1086/656412. Review.</citation>
    <PMID>20839968</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2011</study_first_posted>
  <results_first_submitted>March 6, 2017</results_first_submitted>
  <results_first_submitted_qc>March 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2017</results_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Andrea Branch</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>combination antiretroviral therapy</keyword>
  <keyword>vitamin D</keyword>
  <keyword>low bone density</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Conventional Vitamin D Treatment</title>
          <description>conventional vitamin D treatment: Subjects in Protocol A (the conventional/active placebo arm) received 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.</description>
        </group>
        <group group_id="P2">
          <title>Tiered/Titrated Vitamin D Dosing</title>
          <description>tiered/titrated vitamin D dosing: Subjects in Protocol B received 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Conventional Vitamin B Dosing</title>
          <description>Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.</description>
        </group>
        <group group_id="B2">
          <title>Tiered/Titrated Vitamin B Dosing</title>
          <description>tiered/titrated vitamin D dosing: Subjects in Protocol B received 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" lower_limit="39" upper_limit="51"/>
                    <measurement group_id="B2" value="48" lower_limit="42" upper_limit="52"/>
                    <measurement group_id="B3" value="48" lower_limit="41" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>25(OH)D Levels</title>
        <description>The difference in the percentage of subjects with 25(OH)D levels in the range of 30-60 ng/ml at 12 mo between the two arms.</description>
        <time_frame>baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional Vitamin D Treatment</title>
            <description>conventional vitamin D treatment: Subjects in Protocol A (the conventional/active placebo arm) received 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.</description>
          </group>
          <group group_id="O2">
            <title>Tiered/Titrated Vitamin D Dosing</title>
            <description>tiered/titrated vitamin D dosing: Subjects in Protocol B received 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.</description>
          </group>
        </group_list>
        <measure>
          <title>25(OH)D Levels</title>
          <description>The difference in the percentage of subjects with 25(OH)D levels in the range of 30-60 ng/ml at 12 mo between the two arms.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+T Cell Count</title>
        <description>The change in the CD4+T cell count between the two arms.</description>
        <time_frame>baseline and 12 months</time_frame>
        <population>Analysis only for participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Vitamin B Dosing</title>
            <description>Subjects in Protocol A (the conventional/active placebo arm) received 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.</description>
          </group>
          <group group_id="O2">
            <title>Tiered/Titrated Vitamin D Dosing</title>
            <description>tiered/titrated vitamin D dosing: Subjects in Protocol B received 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+T Cell Count</title>
          <description>The change in the CD4+T cell count between the two arms.</description>
          <population>Analysis only for participants who completed the study.</population>
          <units>cell/Î¼L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="-56" upper_limit="122"/>
                    <measurement group_id="O2" value="40" lower_limit="-45" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Conventional Vitamin B Dosing</title>
          <description>Subjects in Protocol A (the conventional/active placebo arm) received 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.</description>
        </group>
        <group group_id="E2">
          <title>Tiered/Titrated Vitamin B Dosing</title>
          <description>Subjects in Protocol B received 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrea D. Branch PhD</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212 659 8371</phone>
      <email>andrea.branch@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

